KCM
TRVI icon

Kennedy Capital Management’s Trevi Therapeutics TRVI Stock Holding History

Kennedy Capital Management’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.18M Buy
63,108
+1,810
+3% +$26.3K 0.02% 499
2026
Q1 		$731K Buy
61,298
+5,029
+9% +$56.3K 0.02% 504
2025
Q4 		$704K Buy
56,269
+1,336
+2% +$15.4K 0.01% 501
2025
Q3 		$503K Buy
54,933
+27,082
+97% +$203K 0.01% 532
2025
Q2 		$152K Buy
27,851
+595
+2% +$3.7K ﹤0.01% 574
2025
Q1 		$171K Buy
+27,256
New +$130K ﹤0.01% 628

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Kennedy Capital Management's TRVI Position: Q2 2026 in Review

Kennedy Capital Management increased its Trevi Therapeutics (TRVI) stake by 3% in Q2 2026, buying an estimated $26.3K and bringing the position to 63,108 shares worth $1.18M. The position accounts for 0.02% of the portfolio, ranked #499.

Kennedy Capital Management first reported a position in TRVI in Q1 2025 and has held it in 6 quarters since. 219 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Kennedy Capital Management held 63,108 shares of Trevi Therapeutics worth $1.18M as of Q2 2026.
  • Kennedy Capital Management bought 1,810 Trevi Therapeutics shares in Q2 2026, an estimated $26.3K.
  • Trevi Therapeutics made up 0.02% of Kennedy Capital Management's portfolio in Q2 2026, its #499 holding.
  • Kennedy Capital Management first reported a position in Trevi Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 219 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Kennedy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.